Two targeted drugs for relapsed Waldenstrom macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a confirmed diagnosis of Waldenstrom macroglobulinemia with active disease that needs treatment.
- You must have had at least one prior treatment for your Waldenstrom, and you must have either taken a BTK inhibitor (like ibrutinib or zanubrutinib) or decided not to take one.
- You need to be in reasonably good health, with adequate blood counts (though some allowances are made if your bone marrow is involved) and adequate kidney and liver function.
- You must be able to swallow oral tablets and have recovered from any major side effects of prior treatments.
- You cannot have certain prior treatments, such as CAR T-cell therapy within 60 days, or certain antibody treatments within 4 weeks, and you cannot have had a stem cell transplant from a donor.
- You must not have a history of certain conditions, including transformation to aggressive lymphoma, active infections (like HIV or hepatitis), or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
This study tests a combination of new and older drugs for Waldenström macroglobulinemia, a rare blood cancer. The drugs aim to block the cancer's growth signals and boost the body's immune attack. It is for people who have not yet had any treatment for this condition.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.